Research programme: soluble platelet-derived growth factor receptor proteins - Orthogonal Biologics
Latest Information Update: 22 Feb 2022
At a glance
- Originator University of Illinois
- Developer Orthogonal Biologics
- Class Antivirals; Growth factors
- Mechanism of Action Platelet-derived growth factor alpha receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cytomegalovirus infections
Most Recent Events
- 22 Feb 2022 Early research in Cytomegalovirus infections in USA (unspecified route) as of February 2022 (Orthogonal Biologics website; February 2022)
- 06 Dec 2021 Orthogonal Biologics is subsidiary of Cyrus Biotechnology
- 19 Jun 2020 soluble platelet-derived growth factor receptor proteins licensed to Orthogonal Biologics